Abstract

To determine effects of the biochemical and cytological properties of blood, serum, and ascites on survival of patients with malignant peritoneal effusion (MPeE), including malignant peritoneal mesothelioma (MPeM) and peritoneal carcinomatosis (PC), we conducted a retrospective study of patients with MPeE and healthy controls. Potential prognostic factors were identified as follows: age, sex, blood neutrophil-to-lymphocyte ratio (NLR), serum parameters, ascites parameters, serum-ascites albumin gradient, and the ascites-serum LDH ratio. Compared to those of the control group, serum albumin levels were significantly lower, and the NLR and serum LDH levels were significantly higher in the MPeE group. Overall survival (OS) was longer in patients with MPeM compared to that in patients with PC. Compared with patients in the MPeM, patients with PC had higher NLRs, ascites glucose levels, serum-ascites albumin gradients, and serum LDH levels. In contrast, their ascites albumin levels and ascites-serum LDH ratios were lower. Univariate analyses indicated that the NLR, serum LDH levels, ascites LDH levels, ascites coenocyte levels, and the ascites coenocyte-to-monocyte ratios affected the OS. Multivariate analyses identified only serum and ascites LDH levels as independent prognostic factors.

Highlights

  • Malignant peritoneal effusion (MPeE) is a marker that frequently indicates advanced malignant disease, and malignant ascites is a grave prognostic sign

  • Patients were hospitalized because of ascites, and those eligible for inclusion in the study presented with diffuse malignant peritoneal mesothelioma (MPeM) without other primary tumors; patients with peritoneal carcinomatosis (PC) were identified using imaging, peritoneal histopathology, and immunohistochemistry tests administered before treatment [9, 10]

  • We conducted a retrospective analysis of biochemical data and overall survival (OS) collected from 43 patients with MPeM and 82 with PC who were treated at our hospital from January 2012 to January 2017

Read more

Summary

Introduction

Malignant peritoneal effusion (MPeE) is a marker that frequently indicates advanced malignant disease, and malignant ascites is a grave prognostic sign. Tumors causing carcinomatosis are commonly secondary peritoneal surface malignancies as follows: ovarian, colorectal, pancreatic, and uterine. Other causes include extra-abdominal tumors originating from lymphomas, lung and breast cancer, and a small number of primary tumors such as malignant peritoneal mesothelioma (MPeM) [1]. Malignant ascites accounts for approximately 10% of cases of ascites [2]. Survival from time of diagnosis in this patient population is poor, and there are limited therapeutic options with the goal of targeting palliation to symptoms, which include abdominal pain, nausea, vomiting, and anorexia

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call